The main purpose of this legislation is to enhance and clarify the rules regarding orphan drugs within the Drug Price Negotiation Program. Orphan drugs are medications developed specifically to treat rare diseases, and this act aims to ensure that these drugs are treated fairly in terms of pricing and negotiation. Key provisions of the legislation include changes to how the time period for orphan drug approval is calculated.